Contact Dermatitis (Dermatology) Drug Pipeline Landscape Report 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Contact Dermatitis (Dermatology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Contact Dermatitis – Drugs In Development, 2021, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.
Report Highlights
Contact Dermatitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 3 respectively. Similarly, the Universities portfolio in Phase III stages comprises 1 molecules, respectively.
Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)
Key Topics Covered:
Introduction
Contact Dermatitis – Overview
- Contact Dermatitis – Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
Contact Dermatitis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Contact Dermatitis – Companies Involved in Therapeutics Development
- Aposcience AG
- Edesa Biotech Inc
- Hapten Sciences Inc
- ILiAD Biotechnologies LLC
- Signum Dermalogix Inc
Contact Dermatitis – Drug Profiles
- APO-2
- diflucortolone
- EB-01
- EB-05
- HPT-721
- pertussis [strain BPZE1] vaccine
- SIG-1322
Contact Dermatitis – Dormant Projects
Contact Dermatitis – Discontinued Products
Contact Dermatitis – Product Development Milestones
Featured News & Press Releases
- Mar 09, 2021: Edesa Biotech completes enrollment for interim clinical study milestone
- Nov 03, 2020: Edesa Biotech achieves enrollment milestone in dermatitis study
- May 15, 2020: Contact dermatitis: potential new treatments with biologic drug
- Dec 03, 2019: Edesa Biotech reports positive healthy volunteer data and expands Phase 2b Dermatitis Study to patients with Facial Lesions
- Oct 21, 2019: Edesa Biotech enrolls first patient in phase 2b dermatitis study
- Jul 25, 2019: Edesa Biotech completes manufacturing for upcoming dermatitis study
- Jun 20, 2019: Edesa Biotech receives approval to proceed with U.S. clinical study
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/j0ljiy
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
